Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2022 Jan;11(1):129-132.
doi: 10.7774/cevr.2022.11.1.129. Epub 2022 Jan 31.

Alopecia areata after COVID-19 vaccination

Affiliations
Case Reports

Alopecia areata after COVID-19 vaccination

Giuseppe Gallo et al. Clin Exp Vaccine Res. 2022 Jan.

Abstract

The coronavirus disease 2019 (COVID-19) vaccines are authorized for use in numerous countries worldwide. Several cutaneous findings are reported after severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) vaccination. Here, we report the case of a patient with a rapid onset of alopecia areata immediately after receiving the second dose of the COVID-19 vaccine. Alopecia areata is a common autoimmune disease leading to non-scarring hair loss. Among the many cutaneous adverse effects reported after the anti-SARS-COV2 vaccination, no episodes of alopecia areata have been described to date. In this paper, we report the first case of alopecia areata after COVID-19 vaccination described in the literature with a revision of cases of alopecia areata reported after other types of vaccination. Although the significance of these skin reactions is not yet known, further studies will certainly clarify whether the development of alopecia areata or other forms of immune-mediated reactions could represent a positive prognostic factor regarding immune protection from SARS-CoV-2.

Keywords: Alopecia areata; COVID-19; Trichoscopy; Vaccine.

PubMed Disclaimer

Conflict of interest statement

No potential conflict of interest relevant to this article was reported.

Figures

Fig. 1
Fig. 1. Multiple patches of alopecia areata involving the temporo-parietal (A), occipital (B), and vertex areas (C). Patches of alopecia areata involving the beard (D). Written informed consent for publication of this image was obtained from the patient.
Fig. 2
Fig. 2. Trichoscopic pictures showing yellow dots, black dots, dystrophic hairs, and vellus hairs performed at the periphery (A) and center (B–D) of alopecia patches (×10–×50; FotoFinder Dermoscope; Germany). Written informed consent for publication of this image was obtained from the patient.

References

    1. Strazzulla LC, Wang EHC, Avila L, et al. Alopecia areata: disease characteristics, clinical evaluation, and new perspectives on pathogenesis. J Am Acad Dermatol. 2018;78:1–12. - PubMed
    1. Moreno-Arrones OM, Lobato-Berezo A, Gomez-Zubiaur A, et al. SARS-CoV-2-induced telogen effluvium: a multicentric study. J Eur Acad Dermatol Venereol. 2021;35:e181–e183. - PMC - PubMed
    1. Sgubbi P, Savoia F, Calderoni O, Longo R, Stinchi C, Tabanelli M. Alopecia areata in a patient with SARS-Cov-2 infection. Dermatol Ther. 2020;33:e14295. - PubMed
    1. Capalbo A, Giordano D, Gagliostro N, et al. Alopecia areata in a COVID-19 patient: a case report. Dermatol Ther. 2021;34:e14685. - PMC - PubMed
    1. Berbert Ferreira S, Gavazzoni Dias M, Berbert Ferreira R, Neves Neto AC, Trueb RM, Lupi O. Rapidly progressive alopecia areata totalis in a COVID-19 patient, unresponsive to tofacitinib. J Eur Acad Dermatol Venereol. 2021;35:e411–e412. - PMC - PubMed

Publication types